{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Colorectal+Carcinoma&page=24",
    "query": {
      "condition": "Metastatic Colorectal Carcinoma",
      "page": 24
    },
    "page_size": 10
  },
  "pagination": {
    "page": 24,
    "page_size": 10,
    "total_count": 1156,
    "total_pages": 116,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Colorectal+Carcinoma&page=25&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Colorectal+Carcinoma&page=23&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T10:58:18.583Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01183780",
      "title": "A Study in Second Line Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Ramucirumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Folinic Acid",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1072,
      "start_date": "2010-12-02",
      "completion_date": "2016-06-20",
      "has_results": true,
      "last_update_posted_date": "2019-09-25",
      "last_synced_at": "2026-10-16T10:58:18.583Z",
      "location_count": 92,
      "location_summary": "Sedona, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 89 more",
      "locations": [
        {
          "city": "Sedona",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01183780"
    },
    {
      "nct_id": "NCT02599324",
      "title": "Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Renal Cell Carcinoma",
        "Advanced Urothelial Carcinoma",
        "Advanced Gastric Adenocarcinoma",
        "Metastatic Colorectal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "everolimus",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "cetuximab",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharmacyclics LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 263,
      "start_date": "2015-12-01",
      "completion_date": "2021-08-20",
      "has_results": true,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-10-16T10:58:18.583Z",
      "location_count": 44,
      "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Tucson, Arizona + 39 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Daly City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02599324"
    },
    {
      "nct_id": "NCT07044362",
      "title": "Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Liver Metastases",
        "Liver Cancer"
      ],
      "interventions": [
        {
          "name": "HistoSonics Edison® System",
          "type": "DEVICE"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-11-19",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-16T10:58:18.583Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07044362"
    },
    {
      "nct_id": "NCT04670679",
      "title": "A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ERAS-601",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Erasca, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 90,
      "start_date": "2020-12-15",
      "completion_date": "2026-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-10-16T10:58:18.583Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Sarasota, Florida • Boston, Massachusetts + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Henderson",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04670679"
    },
    {
      "nct_id": "NCT03712943",
      "title": "Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Metastatic Colorectal Cancer",
        "Colon Cancer"
      ],
      "interventions": [
        {
          "name": "Regorafenib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2018-10-23",
      "completion_date": "2024-01-18",
      "has_results": false,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-10-16T10:58:18.583Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03712943"
    },
    {
      "nct_id": "NCT02559024",
      "title": "Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "MEDI6469",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2016-03-14",
      "completion_date": "2018-10",
      "has_results": false,
      "last_update_posted_date": "2022-02-14",
      "last_synced_at": "2026-10-16T10:58:18.583Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02559024"
    },
    {
      "nct_id": "NCT03289962",
      "title": "A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Non-Small Cell Lung Cancer",
        "Bladder Cancer",
        "Colorectal Cancer",
        "Triple Negative Breast Cancer",
        "Renal Cancer",
        "Head and Neck Cancer",
        "Other Solid Cancers"
      ],
      "interventions": [
        {
          "name": "Autogene cevumeran",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 273,
      "start_date": "2017-12-21",
      "completion_date": "2025-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-10-16T10:58:18.583Z",
      "location_count": 15,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 10 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03289962"
    },
    {
      "nct_id": "NCT02650635",
      "title": "TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Adenocarcinoma",
        "Metastatic Pancreatic Adenocarcinoma",
        "Recurrent Breast Carcinoma",
        "Recurrent Colorectal Carcinoma",
        "Recurrent Melanoma of the Skin",
        "Recurrent Non-Small Cell Lung Carcinoma",
        "Recurrent Pancreatic Carcinoma",
        "Recurrent Renal Cell Carcinoma",
        "Solid Neoplasm",
        "Stage IV Breast Cancer",
        "Stage IV Non-Small Cell Lung Cancer",
        "Stage IV Renal Cell Cancer",
        "Stage IV Skin Melanoma",
        "Stage IVA Colorectal Cancer",
        "Stage IVA Pancreatic Cancer",
        "Stage IVB Colorectal Cancer",
        "Stage IVB Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "TLR8 Agonist VTX-2337",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2016-02-05",
      "completion_date": "2017-06-01",
      "has_results": false,
      "last_update_posted_date": "2018-09-05",
      "last_synced_at": "2026-10-16T10:58:18.583Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02650635"
    },
    {
      "nct_id": "NCT01931150",
      "title": "Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cetuximab-induced Papulopustular (Acneiform) Rash Who Have",
        "Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Topical Dapsone 5% Gel",
          "type": "DRUG"
        },
        {
          "name": "Moisturizer",
          "type": "OTHER"
        },
        {
          "name": "oral antibiotics",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2013-08",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2017-01-13",
      "last_synced_at": "2026-10-16T10:58:18.583Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01931150"
    },
    {
      "nct_id": "NCT00087191",
      "title": "EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Advanced Adult Primary Liver Cancer",
        "Carcinoma of the Appendix",
        "Fallopian Tube Cancer",
        "Gastrointestinal Stromal Tumor",
        "Localized Extrahepatic Bile Duct Cancer",
        "Localized Gallbladder Cancer",
        "Localized Gastrointestinal Carcinoid Tumor",
        "Localized Resectable Adult Primary Liver Cancer",
        "Localized Unresectable Adult Primary Liver Cancer",
        "Metastatic Gastrointestinal Carcinoid Tumor",
        "Ovarian Sarcoma",
        "Ovarian Stromal Cancer",
        "Primary Peritoneal Cavity Cancer",
        "Recurrent Adult Primary Liver Cancer",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Colon Cancer",
        "Recurrent Extrahepatic Bile Duct Cancer",
        "Recurrent Gallbladder Cancer",
        "Recurrent Gastric Cancer",
        "Recurrent Gastrointestinal Carcinoid Tumor",
        "Recurrent Non-small Cell Lung Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Ovarian Germ Cell Tumor",
        "Recurrent Pancreatic Cancer",
        "Recurrent Rectal Cancer",
        "Recurrent Small Intestine Cancer",
        "Recurrent Uterine Sarcoma",
        "Regional Gastrointestinal Carcinoid Tumor",
        "Small Intestine Adenocarcinoma",
        "Small Intestine Leiomyosarcoma",
        "Small Intestine Lymphoma",
        "Stage 0 Non-small Cell Lung Cancer",
        "Stage I Adult Soft Tissue Sarcoma",
        "Stage I Colon Cancer",
        "Stage I Gastric Cancer",
        "Stage I Non-small Cell Lung Cancer",
        "Stage I Ovarian Epithelial Cancer",
        "Stage I Ovarian Germ Cell Tumor",
        "Stage I Pancreatic Cancer",
        "Stage I Rectal Cancer",
        "Stage I Uterine Sarcoma",
        "Stage II Adult Soft Tissue Sarcoma",
        "Stage II Colon Cancer",
        "Stage II Gastric Cancer",
        "Stage II Non-small Cell Lung Cancer",
        "Stage II Ovarian Epithelial Cancer",
        "Stage II Ovarian Germ Cell Tumor",
        "Stage II Pancreatic Cancer",
        "Stage II Rectal Cancer",
        "Stage II Uterine Sarcoma",
        "Stage III Adult Soft Tissue Sarcoma",
        "Stage III Colon Cancer",
        "Stage III Gastric Cancer",
        "Stage III Ovarian Epithelial Cancer",
        "Stage III Ovarian Germ Cell Tumor",
        "Stage III Pancreatic Cancer",
        "Stage III Rectal Cancer",
        "Stage III Uterine Sarcoma",
        "Stage IIIA Non-small Cell Lung Cancer",
        "Stage IIIB Non-small Cell Lung Cancer",
        "Stage IV Adult Soft Tissue Sarcoma",
        "Stage IV Colon Cancer",
        "Stage IV Gastric Cancer",
        "Stage IV Non-small Cell Lung Cancer",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Ovarian Germ Cell Tumor",
        "Stage IV Pancreatic Cancer",
        "Stage IV Rectal Cancer",
        "Stage IV Uterine Sarcoma",
        "Unresectable Extrahepatic Bile Duct Cancer",
        "Unresectable Gallbladder Cancer"
      ],
      "interventions": [
        {
          "name": "EF5",
          "type": "DRUG"
        },
        {
          "name": "motexafin lutetium",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2004-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-16",
      "last_synced_at": "2026-10-16T10:58:18.583Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00087191"
    }
  ]
}